I. Vergote Et Al. , "ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , vol.37, Illinois, United States Of America, 2019
Vergote, I. Et Al. 2019. ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).
Vergote, I., Sehouli, J., Salutari, V., Zola, P., Madry, R., Wenham, R. M., ... Korach, J.(2019). ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer. . Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America
Vergote, Ignace Et Al. "ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2019
Vergote, Ignace Et Al. "ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2019
Vergote, I. Et Al. (2019) . "ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Ignace Vergote Et Al. }, title={ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.}, congress name={Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2019}}